ANTENGENE-B (06996) opened more than 11% higher. At the time of writing, the stock was up 11.11% at HK$3.2, with a turnover of HK$659,200. The move follows an announcement that ANTENGENE and UCB have entered into an agreement. Under the terms, ANTENGENE grants UCB exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager antibody ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, comprising a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to over $1.1 billion in future milestone payments, plus tiered royalties based on future net sales. ANTENGENE plans to submit a clinical trial application for ATG-201 in China and Australia in the first quarter of 2026 and will conduct the first-in-human (Phase I) clinical study in these regions. Subsequent clinical development and related activities for ATG-201 will then be transferred to UCB.